Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06988020 | "Pseudo-scanner" MRI Sequences for the Detection of Bone Lesions in Multiple Myeloma(MM-ZTE-II) | recruiting | N/A | 45 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03633955 | Pilot Imaging Study of Leukemia(REALIZE) | recruiting | Phase 1 | 60 | University of OklahomaOTHER | 1 | Apr 23, 2026 |
| clinicaltrials |
| NCT04627753 | Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.(Lemon-C) | recruiting | Phase 2 | 30 | Kim, Seok JinOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04989621 | Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL) | recruiting | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05245656 | A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma | recruiting | Phase 2 | 90 | Kim, Seok JinOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06263491 | Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients | recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07097363 | Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 2 | 18 | University of WashingtonOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07214324 | Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution(PNRR-2022-1237) | recruiting | — | 60 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07547007 | Benefits of a 6-month, Individualized, Hybrid, "Real-life" Adapted Physical Activity Program on the Quality of Life of Patients Treated for Multiple Myeloma(BAPAMM) | recruiting | N/A | 86 | Centre Hospitalier Metropole SavoieOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07548697 | A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma | recruiting | Early Phase 1 | 24 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03523975 | Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 28 | City of Hope Medical CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03823534 | Post-Op Pain Control for Prophylactic Intramedullary Nailing. | recruiting | Phase 3 | 60 | St. Louis UniversityOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05972135 | Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma | recruiting | Phase 2 | 100 | SCRI Development Innovations, LLCOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT06386315 | Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma | recruiting | Phase 2 | 112 | Mayo ClinicOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT06839053 | Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma | recruiting | Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07545603 | Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma | recruiting | Phase 2 | 65 | Evopoint Biosciences Inc.INDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07546188 | AI-based Predictive and Interventional System for Early Detection of Non-compliance Risks With Oral Therapies in Lymphoma Patients.(LNH-AI-Tools) | recruiting | — | 210 | Grand Hôpital de CharleroiOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT02726750 | Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma | recruiting | — | 200 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05646576 | Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy(PEACE) | recruiting | N/A | 90 | Massachusetts General HospitalOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT03761108 | Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma(LINKER-MM1) | recruiting | Phase 1 / Phase 2 | 387 | Regeneron PharmaceuticalsINDUSTRY | 7 | Apr 20, 2026 | clinicaltrials |
| NCT05909059 | CAR T-cell Therapy in Patients With Renal Dysfunction | recruiting | Phase 2 | 20 | Northside Hospital, Inc.OTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06859008 | Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 37 | City of Hope Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07496229 | Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) | recruiting | Phase 1 / Phase 2 | 165 | Dizal PharmaceuticalsINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03328078 | CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) | recruiting | Phase 1 / Phase 2 | 152 | Curis, Inc.INDUSTRY | 7 | Apr 16, 2026 | clinicaltrials |
| NCT04839003 | A Registry of AL Amyloidosis (ReAL)(ReAL) | recruiting | — | 5,000 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05640843 | A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) | recruiting | N/A | 180 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06205953 | A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)(EUREKA) | recruiting | — | 400 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 6 | Apr 16, 2026 | clinicaltrials |
| NCT06383143 | Promoting Diagnosis and Management of AL in Italy (ProDigALIty)(ProDigALIty) | recruiting | — | 760 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06385652 | PET Imaging Study of 68Ga-NB381 in Multiple Myeloma | recruiting | Early Phase 1 | 30 | Peking University First HospitalOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06484777 | A Clinical Study of SHR-9539 in Patients With Multiple Myeloma | recruiting | Phase 1 | 138 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03398161 | Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides | recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04491370 | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 20 | New York Medical CollegeOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05136807 | Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies | recruiting | — | 400 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05336383 | Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06839456 | Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT | recruiting | Phase 1 / Phase 2 | 100 | Children's Hospital of PhiladelphiaOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07107529 | Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. | recruiting | Phase 2 | 150 | European Myeloma Network B.V.NETWORK | 4 | Apr 15, 2026 | clinicaltrials |
| NCT07356245 | Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma | recruiting | Phase 2 | 44 | Jonathan BrammerOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07523737 | Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma | recruiting | Phase 2 | 43 | Beijing Tongren HospitalOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05996185 | Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma | recruiting | Phase 2 | 22 | Yale UniversityOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT06544265 | SynKIR-310 for Relapsed/Refractory B-NHL | recruiting | Phase 1 | 36 | Verismo TherapeuticsINDUSTRY | 1 | Apr 14, 2026 | clinicaltrials |
| NCT01890486 | The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen | recruiting | — | 2,000 | Wake Forest University Health SciencesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06145581 | Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma | recruiting | N/A | 25 | Mayo ClinicOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06923397 | Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial | recruiting | N/A | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07032714 | Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma(MAGENTA) | recruiting | Phase 1 | 25 | Massachusetts General HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07260812 | KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 1 | 18 | TCRx Therapeutics Co.LtdINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07523555 | Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies(ADAPT-HEM) | recruiting | Phase 1 / Phase 2 | 96 | Beijing BiotechINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07525466 | Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH) | recruiting | Phase 1 / Phase 2 | 25 | Beijing Tongren HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04234022 | Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma | recruiting | — | 70 | The Royal Wolverhampton Hospitals NHS TrustOTHER_GOV | 1 | Apr 9, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 24, 2026source: clinicaltrials